Sanofi-Aventis agrees $165 million deal with AEterna Zentaris
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis has signed a $165 million licensing deal with AEterna Zentaris for the Canadian company's benign prostatic hyperplasia (BPH) treatment cetrorelix. Sanofi-Aventis has acquired the US rights to develop and bring to market the compound, which is in Phase III studies.